Intensity Therapeutics (Nasdaq: INTS) Stock: Announces 1-for-25 Reverse Split to Meet Nasdaq Rule

TLDR:

• INTS sets 1-for-25 reverse split for Feb 18, with trading Feb 19

• Reverse split cuts INTS shares to about 2.53M while keeping authorization

• INTS adjusts options and warrants proportionally and pays cash for fractions

• Company targets higher share price to regain Nasdaq minimum bid compliance

• Split changes CUSIP and keeps ticker INTS as clinical programs continue

Intensity Therapeutics (Nasdaq: INTS) stock traded near $0.2706 as the company set a 1-for-25 reverse split. The change takes legal effect at 4:01 p.m. ET on February 18, 2026. Trading begins February 19 on a split-adjusted basis under INTS.

Intensity Therapeutics, Inc., INTS

Reverse split targets Nasdaq bid-price compliance

Intensity Therapeutics approved a 1-for-25 reverse split to increase its per-share trading price. The company aims to regain compliance with Nasdaq’s minimum bid price requirement. Therefore, the action supports continued listing on the Nasdaq Capital Market.

Shareholders approved the reverse split at a special meeting held on October 22, 2025. The board then set the effective time and the start of split-adjusted trading. As a result, the company aligned governance steps with listing requirements.

The reverse split will convert every twenty-five common shares into one common share automatically. The company will not issue fractional shares after the conversion. Instead, it will pay cash for any fractional entitlements.

Share count falls sharply while terms adjust proportionally

The reverse split will reduce outstanding common shares from about 63,346,579 to about 2,533,863. The company based those figures on shares outstanding as of February 12, 2026. However, it will keep the total authorized share count unchanged.

The company will adjust exercise prices and conversion prices for options, warrants, and convertible securities proportionally. It will also adjust share counts under equity plans to reflect the split ratio. Consequently, contract economics stay consistent while share numbers change.

The company will assign a new CUSIP number for split-adjusted trading on Nasdaq. The ticker symbol will remain INTS, and trading will resume on February 19. Therefore, market systems will reflect the new share structure without a ticker change.

Shareholder handling and business context remain central

Holders with book-entry shares will receive post-split shares automatically without required action. Brokers and nominees will adjust positions based on their internal processes. As a result, most holders should see updated share counts through standard account reporting.

Holders with physical certificates will receive instructions from the transfer agent for exchange procedures. The process will convert certificates into book-entry shares or issue new certificates when needed. Additionally, the agent will deliver any cash-in-lieu amounts where applicable.

Intensity continues clinical development of INT230-6, an intratumoral investigational therapy that combines cisplatin and vinblastine with a dispersing enhancer. The company has enrolled over 200 patients across completed studies and ongoing trials. Meanwhile, the reverse split focuses on listing compliance while the pipeline advances.

The post Intensity Therapeutics (Nasdaq: INTS) Stock: Announces 1-for-25 Reverse Split to Meet Nasdaq Rule appeared first on CoinCentral.